{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:53:10Z","timestamp":1793310790504,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332022012"],"award-info":[{"award-number":["3332022012"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005153","name":"China National Funds for Distinguished Young Scientists","doi-asserted-by":"publisher","award":["82202541"],"award-info":[{"award-number":["82202541"]}],"id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UHB12396"],"award-info":[{"award-number":["UHB12396"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jgar.2025.09.011","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:46:53Z","timestamp":1759009613000},"page":"196-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The efficacy and safety of eravacycline in the treatment of patients with pneumonia in respiratory departments: A real-world multicenter retrospective study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2632-4892","authenticated-orcid":false,"given":"Zhengyu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minya","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.09.011_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.jgar.2025.09.011_bib0002","first-page":"S397","article-title":"Combating antimicrobial resistance: policy recommendations to save lives","volume":"52","author":"Spellberg","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.09.011_bib0003","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ajic.2018.03.013","article-title":"Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: shifting burden of disease?","volume":"46","author":"Britt","year":"2018","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jgar.2025.09.011_bib0004","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.09.011_bib0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jgar.2021.02.009","article-title":"Efficacy and safety of eravacycline: a meta-analysis","volume":"24","author":"Eljaaly","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.09.011_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: a novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.09.011_bib0007","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jgar.2025.09.011_bib0008","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.09.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107341","article-title":"In-vitro activities of essential antimicrobial agents including aztreonam\/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multi-centre study in China, 2021","volume":"64","author":"Wu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.09.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117666","article-title":"Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing enterobacterales and Acinetobacter baumannii","volume":"181","author":"Garc\u00eda","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jgar.2025.09.011_bib0011","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.09.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2025.09.011_bib0013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline","volume":"9","author":"Van Hise","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.09.011_bib0014","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2025.09.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious Diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.09.011_bib0016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/antibiotics9030119","article-title":"Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen","volume":"9","author":"Ayoub Moubareck","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.09.011_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1417237","article-title":"Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China","volume":"15","author":"Chen","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2025.09.011_bib0018","article-title":"Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jgar.2025.09.011_bib0019","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.28.2400019","article-title":"Nosocomial transmission of tet(x3), bla NDM-1 and bla OXA-97-carrying Acinetobacter baumannii conferring resistance to eravacycline and omadacycline, the Netherlands, March to August 2021","volume":"29","author":"Talsma","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2025.09.011_bib0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/antibiotics12020234","article-title":"Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options","volume":"12","author":"Karampatakis","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.09.011_bib0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s15010-021-01735-1","article-title":"Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates","volume":"50","author":"Maraki","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2025.09.011_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41426-018-0141-y","article-title":"Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae","volume":"7","author":"Zheng","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jgar.2025.09.011_bib0023","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jiph.2024.03.027","article-title":"Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae","volume":"17","author":"Huang","year":"2024","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2025.09.011_bib0024","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","article-title":"Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli: a Chinese consensus statement","volume":"22","author":"Guan","year":"2016","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.jgar.2025.09.011_bib0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.09.011_bib0026","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/1120009X.2021.2005755","article-title":"In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii","volume":"34","author":"Yin","year":"2022","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2025.09.011_bib0027","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by gram-negative pathogens: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:02:39Z","timestamp":1780783359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"alternative-id":["S2213716525002152"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.09.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of eravacycline in the treatment of patients with pneumonia in respiratory departments: A real-world multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}